#experimentica
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
In 2020, 27% of US Tumblr users had an annual household income of over $100,000.
Text
Abbreviated Exhibitions CV
O
My Career has been disrupted for thirteen years by the Invasive Gangstalking brought by the Ringleader and Paedophile Ring Internet Criminal SARAH TREGONNING...
That began covertly in 2011 with threats commencing in September 2013...
I began writing The Impossible in 2014... and making it public in order to bring Justice, Defend Self and Children and SAVE LIVES in the Winter of 2015...
I have been in and out of Physical and Digital Hiding since 2013
The Impossible is a groundbreaking contemporary artwork which is multidisciplinary and A LIVED ARTWORK...
It is a body of work which takes place and exists offline and online and on Multiple Planes
Holy Opus O V
In February 2019 I was forcibly possessed by the Fallen Archangel Gabriel who desired to use a Holy Goddess's Body, Life and Soul as an Instrument of its own expressions...
This is a Forbidden and Condemned Act from a Fallen Lunic Angel
Angels Inspire ALL SOULS V
Exhibitions Include:
TATE MODERN Tweet Me Up August 2012 (25><28 collaboration)
ABC GALLERY Moscow Infinite Longing May- June 2006
TATTON PARK BIENNIAL Manchester Sep 2008
ICA London April 2005
FACT Liverpool March 2005
PHOENIX ARTS Leicester March 2005
SIDE CINEMA Newcastle March 2005
CASTLEFIELD GALLERY Manchester Feb 2005 / Nov 2004
G39 Cardiff If You Build It They Will Come Aug 2008
CYWAITH CYMRU Cardiff, Say A Little Prayer May 2006
MAC Birmingham March 2006
NATIONAL MUSEUM OF WALES Cardiff Dec 2005
CHAPTER Cardiff Experimentica Nov 2000
MRC Centenary at BAY ART How The Light Gets In July 2013
GOAT MAJOR PROJECTS The Witching Hour Oct/Nov 2012
ART IN THE WAREHOUSE The Crying Counsellor (performance) Dec 2012
Film Festivals:
Fresh Film Festival (Winner of Best Live Action Drama)
International Welsh Film Festival, Cardiff
Clermont-Ferrand, France
Festival L’Etrange, Paris
Int’l Short Film Festival Kracow, Poland
Critics Fortnight (Cannes), France
Cinema Jove, Valencia, Spain
Vila Do Conde Short Film Festival, Portugal
Melbourne Int’l Film Festival, Australia
Sao Paulo Int’l Film Festival, Brazil
Molodist Int’l Festival, Kiev, Ukraine
Cork Int’l Film Festival, Ireland
Uppsala International Film Festival, Sweden
Puchon, Korea
Almeria Short Film Festival, Spain
Dead by Dawn Film Festival, Scotland
Umea International Film Festival, Sweden
Berlin Interfilm Festival, Germany
Leeds International Film Festival, England
V
0 notes
Photo
🟢👉 Deadline Monday 15 February @chaptertweets '#EXPERIMENTICA Presents'. Three new commissions, £1,000 fee each. If you make #LiveArt and #ExperimentalPerformance, and are based in the UK, then we'd like to hear from you! More information and apply for the commission online at www.chapter.org/news (link to website in bio) We're also delighted to announce that artist Jonny Cotsen will be joining the selection panel. Jonny performed at EXPERIMENTICA in 2017 with Louder Is Not Always Clearer. Produced and directed by @dasclarks it has since gone on to tour across the UK and Europe including a hugely successful run at 2019’s Edinburgh Fringe and most recently at @theatredelaville_paris Image: Jonny Cotsen, Louder is Not Always Clearer, EXPERIMENTICA, 2017, Chapter. 📷 Warren Orchard #ArtOpp #Wales #UK #Artists #CallOutForArtists #ArtistCallOut #ApplyNow #LiveArt #Performance #ExperimentalPerformance #Artist #UKArtists #ArtsWales #ArtsinWales #ArtsinCardiff #ArtistOpportunity #ChapterArts #Commissions #ArtistCommissions #ArtistCommission https://www.instagram.com/p/CLP2qgxlM3a/?igshid=190njuoek6mkj
#experimentica#liveart#experimentalperformance#artopp#wales#uk#artists#calloutforartists#artistcallout#applynow#performance#artist#ukartists#artswales#artsinwales#artsincardiff#artistopportunity#chapterarts#commissions#artistcommissions#artistcommission
0 notes
Text
We Live Artist of the Week: Procrastinatrix
youtube
We Live is more than just your average morning radio show taking place in the middle of the zombie apocalypse. Sure, guests call from all over the world and end their interview by getting eaten by zombies live on the air. Sure, these guests are athletes, musicians, artists, actors, journalists, and overall legends. But We Live is more than listening to hilarious interviews that always end the same way - people dying. It also is a show that plays the best indie and underground music on planet Earth.
The governments of the world have collapsed. Zombies lurch on every corner of the world. The living are encouraged to stay home and stay safe. But that doesn’t seem to happen. The world goes on, just with zombies. And since all bets are off, that means the industry conglomerates no longer own the radio waves. Thanks to the end of civilization as we know it, and the rise of undead ghouls, we all get to listen to amazing music from phenomenal artists.
We Live boasts the best underground music library from indie artists anywhere that the living still survives. Every week, we bring you music from around the globe that you would most likely never hear anywhere else. We’ll prove it. Go ahead and check out our Bandcamp page. And those are just some of our celebrated artists. We also search abandoned record stores and music studios for CDs, tapes, records, and even 8-tracks of forgotten or never “broke-through” musicians. We also search Soundcloud and Spotify for artists waiting to get noticed.
Every week, we highlight one particular artist or band that we think you’ll really enjoy regardless of your taste in music. This week, that band is PROCRASTINATRIX.
Music Gateway had this to say about the Welsh techno innovator: Based near Ystradgynlais, Procrastinatrix is a prolific Electronic Music artist with 10 albums & EP’s under his belt. He spends most of his time avoiding practical tasks and instead channeling his creativity into Ableton making spooky, off-kilter beats. Somewhere between Synth-pop and Experimentica, his music is at once catchy, discombobulating, hypnotic, wonky & strangely listenable. If you had to pin him to a genre, he’d say it’s Neo-Nostalgia. You can read the post here. Procrastinatrix’s music is covered throughout all of Episode 4 titled “Ashes to Ashes”. Listen to We Live on Spotify and enjoy every episode HERE. You can take a listen to their song on this week’s episode in the link below. Also remember that our 24/7 Deadline messaging phone number is open for voicemail or text. If you have anyone you’d like us to discover, please let us know at +1(360)836-0628.
2 notes
·
View notes
Text
Exclusive interview with ForwardVue Pharma released for Ophthalmic Drugs 2020
SMi reports: Alan Franklin, CEO, ForwardVue Pharma will be presenting at the Ophthalmic Drugs conference The 4th Annual Ophthalmic Drugs Conference taking place on the 23rd -24th November 2020, will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.
In the run up to the conference, Alan Franklin, CEO, ForwardVue Pharma is interviewed by SMi Group to discuss his presentation details, insights of the Ophthalmic market and his thoughts on the biggest growth area and key developments that have taken place in the last year.
Those who register by the 30th September will save £100 with the early bird discount: http://www.ophthalmicdrugs.com/pharmapr4
Snapshot of Alan’s interview:
The ophthalmic drugs industry is maturing each year, in your opinion, what are the key developments that have taken place in the last year?
“The key news to me is the lack of development of approved and late stage anti-angiogenic molecules. Brolucizumab was approved, but it is associated with a small risk of occlusive vasculitis which can lead to profound, irreversible vision loss. Therefore, brolucizumab has not been widely adopted. The NDA for Abicipar pegol, which utilizes DARPin technology was rejected by the FDA secondary to concerns of inflammation with the 2 mg dose”.
What current topic will you be addressing in your presentation, and what would you say makes it relevant to 2020?
“We believe that stable small molecule therapy will offer both efficacy and durability advantages to the current treatment paradigm for common retinal diseases such as diabetic retinopathy, DR, and neovascular age related macular degeneration, nAMD”.
The brochure with the full interview, agenda and speaker line up is available online at:
http://www.ophthalmicdrugs.com/pharmapr4
Ophthalmic Drugs Conference
23rd -24th November 2020
#OphthalmicDrugs
Proudly sponsored by Experimentica
For exclusive tailored sponsorship packages contact: Alia Malick on +44 (0)20 7827 6168 or email [email protected]
For media queries please contact Jinna Sidhu [email protected] or call +44 (0)20 7827 6088.
—End—
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
The post Exclusive interview with ForwardVue Pharma released for Ophthalmic Drugs 2020 appeared first on .
from https://pharmaphorum.com/partner-content/exclusive-interview-with-forwardvue-pharma-released-for-ophthalmic-drugs-2020/
0 notes
Text
Preclinical CRO Market Growing Strong-MRFR
Preclinical CRO Market Overview:
The global market for the preclinical CRO market is getting backed by several factors like increasing investment in the pharmaceutical and biopharmaceutical sector, availability of additional value-added services, mutual benefits, a surge in the number of drugs for preclinical phase, and others. The global market is on track to surpass a valuation worth USD 5234.7 million during the forecast period of 2019 to 2024, with a CAGR of 8.14%. The constant growth in outsourcing can also propel the market’s growth.
FREE SAMPLE COPY OF “Preclinical CRO Research Report- Global forecast till 2024”@ https://www.marketresearchfuture.com/sample_request/7274
Preclinical CRO Market Segmentation:
The global market for preclinical CRO has been segmented on the basis of service, application, and end user to facilitate a study that would ease the process of deciding the future course of action. These segments will also reveal details regarding factors and their impact on production volume and revenue.
By service, the global preclinical CRO market has been segmented on the basis of toxicology testing, bioanalysis, drug metabolism and pharmacokinetics (DMPK) studies, and others. The toxicological testing segment will lead the global segment and its market valuation can surpass USD 2,476.28 Million by the end of 2024.
By application, the market study reveals segments like oncology, central nervous system (CNS) disorders, immunological disorders, respiratory diseases, cardiovascular diseases, diabetes, infectious diseases, and others. The growing occurrence of cardiovascular diseases can provide traction to the market. The oncology segment can also impact substantially.
By end user, the global market is getting studied on the basis of pharmaceutical and biopharmaceutical industries, medical device companies, and academic institutes. The pharmaceutical and biopharmaceutical industries are expected to make good ground as the investment in rising in the sector.
Preclinical CRO Market Regional Analysis:
The Americas had an over 40% market share in 2018, which made them the largest contributor. This control over the global market is expected to continue. Asia Pacific has the chance to outpace others with a 9.44% CAGR during the forecast period.
Preclinical CRO Market Competitive Landscape:
The global market for preclinical CRO us depending largely on the contributions made by companies like Envigo (US), Charles River (US), IQVIA (US), PAREXEL International Corporation (US), PRA Health Sciences (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), ICON PLC (Dublin), Pharmaceutical Product Development, LLC (US), Medpace (US), Laboratory Corporation of America Holdings (US), and MD Biosciences (US). Their endeavors are mainly focused on expanding the market reach and portfolio. For this, they took the routes concerning mergers, collaborations, acquisitions, innovations, spurring their expenditure for the research and development sector, and others. This also included a detailed approach dealing with marketing strategies like branding and launching plans. MRFR listed the latest changes in their report to make the study more comprehensive.
OBTAIN RESEARCH REPORT DETAILS WITH Considering Covid19 Impact on this Report @ https://www.marketresearchfuture.com/reports/preclinical-cro-market-7274
Industry News:
In May 2020, Experimentica Ltd. announced that they have taken over the contract research division from Ophthy-DS, Inc. with a specialization in non-regulated drug discovery services and medical device testing for diverse ophthalmic indications. The company has made a significant name in the market as a leader in preclinical ophthalmic drug discovery services. Ophthy-DS, Inc. is a Michigan-based company with a substantial impact on the preclinical contract research organization (CRO) segment. This acquisition with cement Experimentica’s position in North America and boost its position as a leading service provider.
In May 2020, Altogen Labs announced that they would be offering in vivo xenograft efficacy studies and pharmacology/toxicology services that have been designed to increase the speed of preclinical research and drug development. The company has already made a name in the market as a GLP-compliant contract research laboratory (CRO).
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
0 notes
Text
SMi presents the launch of… Ophthalmic Drugs
SMi presents the launch of… Ophthalmic Drugs
Date: 28th – 29th November 2017 Location: London, UK Website: www.ophthalmicdrugs.com/ipi Sponsors: Experimentica and Leica Microsystems About Ophthalmic Drugs SMi Group are thrilled to announce the launch of the Ophthalmic Drugs Conference, being held on the 28-29 November 2017 at the Copthorne Tara Hotel in London, UK. www.ophthalmicdrugs.com/ipi Ocular disease therapy has seen a surge in…
View On WordPress
0 notes
Link
Line up for Experimentica 2010 in Cardiff - featuring Outdoor Sports
0 notes
Photo
Support #Experimentica. Help Chapter to continue bringing experimental performance art to Cardiff. http://thndr.me/ndNn1z
0 notes
Photo
The ‘anti-spectacular’ Alternate with Sian Robinson Davies
Two performers talk, speaking alternate words. They use this method to see what happens to meaning when they can only plan one step at a time. Attempting to ‘listen ahead’ to one another, they often find their way to surprising places; places they doubt either one of them would have got to on their own.
Experimentica Festival 15, Chapter Arts, Cardiff, UK Photo: Warren Orchard
0 notes
Text
Send us your thoughts and ideas for the 17th
U T O P I A
PROLOGUE
Paul Becker & The Black Kettle Collective
++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Beginning at the beginning….Artist Paul Becker will be the first to work with Arts Birthday Wales UTOPIA project. In what we hope will be a year of collaboration, reading, exchange and events, Paul will launch the project collaborating with the Swansea based, Black Kettle Collective.
Dylan Thomas Theatre, Gloucester Place, Swansea.
On the 17th of January come along to the Dylan Thomas Theatre, Swansea, to see a performed work based on the prologue of the seminal text. Commissioned by Arts Birthday Wales and Glynn Vivian Art Gallery, Paul Becker will create an environment and perforative elements in the iconic theatre, there will be other events and happenings on the night as we launch a year long project. Paul will also be collaborating with the Black Kettle Collective, the Glynn Vivian's Young Artists group through the galleries diverse and exciting learning and education projects.
Paul Becker is an artist working in the UK exhibiting, publishing and performing nationally and internationally. Based in Newcastle Paul has close connections to Chapter Arts centre where he has exhibited and participated in the performance festival Experimentica.
Paul Becker, Paul Becker I competitori 2009
I am a painter and writer working with a wide variety of influences (Literature, Film, History, Art History etc.) My work is especially concerned with narrative and attempts to view all of the above areas through the prism of painting, allowing for ambiguity in the content of the work itself as well as the blurring of boundaries between subject areas.
Paul Becker
INVITATION TO PARTICIPATE
To inform the performance we invite keywords, short statements, even images in response to the question: What do you find in Utopia? Please send your responses to [email protected] with the subject heading UTOPIA.
We'll post some o the blog over the next few days! Look forward to hearing from you!
SOUNDTRACK
Have you read Utopia by Thomas Moore? If not here's an audio recording to get you inspired to send us your words and suggestions for the 17th.
http://www.learnoutloud.com/Podcast-Directory/Philosophy/Ancient-and-Medieval-Philosophy/Utopia-Podcast/23673#plink
0 notes
Text
Ophthalmic Drug Delivery Development – Trials and Tribulations workshop
SMi reports: Brian Levy, CEO, Ocunexus Therapeutics will lead the post conference workshop on Wednesday 25th November 2020.
SMi presents the 4th Annual Ophthalmic Drugs Conference taking place on the 23rd -24th November 2020, in London. SMi are also pleased to announce that they will be hosting a half-day post-conference workshop, Wednesday 25th November 2020 at 13.30 – 17.30.
Those who register by the 30th September will save £100 with the early bird discount: http://www.ophthalmicdrugs.com/pharmapr3
Workshop will be on ‘Ophthalmic Drug Delivery Development – Trials and Tribulations’. Hosted by Brian Levy, CEO, Ocunexus Therapeutics.
Ophthalmic Drug Delivery is compelling for many reasons, including the major issue of patient compliance and tolerability of therapies.
The complexity of the diseases affecting the eye which encompasses both the anterior segment and posterior segment generally requiring unique technologies with respect to effective drug delivery.
When approaching the potential for drug delivery to the eye many issues come into play including the disease process, the therapeutics and regimen required, the pharmacology and pharmacokinetics, the administration of the drug to be delivered, the formulation and manufacturing issues for delivery systems, cost of goods, regulatory landscape globally and clinical trial strategies, safety concerns, availability of adequate preclinical models and reimbursement environment globally.
Benefits of attending:
Identifying unmet clinical needs favouring DD technology
Understanding the pharmacological challenges for DD and development pathway including cost and timelines
Appreciating the science and art of formulating DD products
Regulatory landscape for product approval
About the workshop leader
Brian Levy is the CEO of Ocunexus Therapeutics a clinical stage company developing products targeting the innate NLRP3 inflammasome in pathological autoinflammation.
Interested parties can learn more about the workshop and full agenda by visiting: http://www.ophthalmicdrugs.com/pharmapr3
Ophthalmic Drugs Conference
23rd -24th November 2020
#OphthalmicDrugs
Proudly sponsored by Experimentica
For exclusive tailored sponsorship packages contact: Alia Malick on +44 (0)20 7827 6168 or email [email protected]
For media queries please contact Jinna Sidhu [email protected] or call +44 (0)20 7827 6088.
—End—
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
The post Ophthalmic Drug Delivery Development – Trials and Tribulations workshop appeared first on .
from https://pharmaphorum.com/partner-content/ophthalmic-drug-delivery-development-trials-and-tribulations-workshop/
0 notes
Text
Aerie Pharmaceuticals interview released for Ophthalmic Drugs Conference
SMi Group Reports: Vice President of Aerie Pharmaceuticals to present at SMi’s Ophthalmic Drugs conference commencing on 18th– 20th November 2019 in London.
SMi catches up with Aerie Pharmaceuticals Vice President, Chemistry, Mitchell de Long as a speaker for the Ophthalmic Drugs conference taking place on the 18th– 20th November 2019 in London. As Europe’s leading Ophthalmic Drugs conference, the three-day agenda will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort, and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.
Snapshot of Mitchell’s interview:
The ophthalmic drugs market has matured greatly over recent years, what are the key significant developments you have noticed over the past year?
“The launch in the US of Rocklatan is certainly the most significant new development in the past year, as it marks the first approval by the US FDA of a combination drug containing a prostaglandin analogue (PGA). Also, of note is Allergan’s filing of an NDA in the US for an intracameral implant of bimatoprost, a prostaglandin analogue. This would mark the first time a PGA would be delivered by injection into the eye, as opposed to by an eyedrop. Other novel molecules that have launched in the past few years will also prove interesting as they find their niche in a suddenly more crowded marketplace.”
What do you personally see as the greatest challenge to overcome in the field of Ophthalmic Drugs at the moment?
“Since the last flurry of new ophthalmic drugs was launched, the reimbursement situation in the US has become much more complex and poses a significant challenge to the US launch of new drugs…”
For the full speaker interview, speaker line-up and more content including the latest brochure and past attendees, it is available to download at www.ophthalmicdrugs.com/pr5
Proudly sponsored by: EXPERIMENTICA | ProMed Pharma
Contacts:
Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 / [email protected]
Media enquiries contact Neill Howard +44 (0) 207 827 6164 / [email protected]
The post Aerie Pharmaceuticals interview released for Ophthalmic Drugs Conference appeared first on Pharmaphorum.
from Pharmaphorum https://pharmaphorum.com/partner-content/aerie-pharmaceuticals-interview-released-for-ophthalmic-drugs-conference/
0 notes
Text
NICOX discusses New Glaucoma Treatment at SMi’s 3rd Ophthalmic Drugs Conference
SMi Group Reports: NICOX recently announced that they have successfully tested a new treatment for the reduction of intraocular pressure in glaucoma. The NCX 470 Clinical Study went head-to-head on a daily dose of the treatment versus Latanoprost, which is perceived as the number one treatment for glaucoma and ocular hypertension.
Gavin Spencer who is Executive Vice President & Chief Business Officer, will be presenting at the third annual Ophthalmic Drugs Conference, where he will discuss the development of NCX 470. He will also focus on the role of nitric acid in control intraocular pressure and future generation compounds from the NICOX platform.
On Day Two of the conference, under the same discussion point on New Developments in Ophthalmic Clinical Trials and Drug Development, Parisa Zamiri, Global Head of Clinical Development in Ophthalmology at Novartis Pharmaceutical will discuss the transformation of future eye care and Virginia Calder, Reader in Ocular Immunology from UCL Institute of Ophthalmology highlights the use of experimental models to identify potential anti-inflammatory drugs in allergic conjunctivitis and uveitis.
Other high-profile speakers presenting include: Aniz Girach, Chief Medical Officer, ProQR Therapeutics Daniel Chung, Global Medical Strategy Lead-Ophthalmology, Spark Therapeutics Michael Ehrlich, Senior Clinical Program Lead – Retinopathies, Boehringer Ingelheim Peter Morgan-Warren, Medical Assessor, MHRA
Further details about the event can be found on the website www.ophthalmicdrugs.com/pr4
Sponsored by: EXPERIMENTICA | ProMed Pharma
Contacts:
Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 / [email protected] Delegate enquiries: contact Alex Vidic on: +44 (0) 20 3866 0221 / [email protected] Media enquiries contact Neill Howard +44 (0) 207 827 6164 / [email protected]
The post NICOX discusses New Glaucoma Treatment at SMi’s 3rd Ophthalmic Drugs Conference appeared first on Pharmaphorum.
from Pharmaphorum https://pharmaphorum.com/partner-content/nicox-discusses-new-glaucoma-treatment-at-smis-3rd-ophthalmic-drugs-conference/
0 notes
Text
Speaker Interview with iVeena Released for 3rd Ophthalmic Drugs Conference
SMi Group reports: Senior expert from iVeena is set to present at SMi’s 3rd Annual Ophthalmic Drugs 3 Day Conference taking place in London on 18 – 20 November 2019.
Europe’s leading Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.
In the run up to the conference, SMi Group caught up with Mike Burr, Vice President of Product Development at iVeena, to discuss his upcoming presentation and his thoughts on the current challenges and opportunities in Ophthalmic Drug development.
A snapshot of Mike Burr’s interview:
Q.The ophthalmic novel drug delivery market has matured greatly over recent years, what are the key significant developments you have noticed over the past year? A. “For decades now there has been research in both academia and industry into longer term (beyond one day) sustained delivery technologies for direct ocular applications with minimal translation into commercial products. Regulatory approvals by the FDA in the last year in the post-cataract space for treatments intended to replace daily anti-inflammatory eye drops is very exciting. There is also a robust pipeline of sustained delivery glaucoma therapies which could provide chronic IOP lowering capabilities in the near term.”
Q.What do you personally see as the greatest challenge to overcome in ophthalmic drug delivery at the moment?
A.“Now that we are seeing the commercialisation of small molecule sustained release products, with hopefully more to come in the near term, the next frontier is in biologics. Large molecule stability for controlled release applications is a tough one.”
The full speaker interview and more content including the latest brochure and past attendees can be found in the DOWNLOADS section on the website at www.ophthalmicdrugs.com
Sponsored by: EXPERIMENTICA | ProMed Pharma
Contacts:
Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 / [email protected]
Delegate enquiries: Kieran Ronaldson on +44 (0) 20 7827 6744 / [email protected]
Media enquiries contact Neill Howard +44 (0) 207 827 6164 / [email protected]
The post Speaker Interview with iVeena Released for 3rd Ophthalmic Drugs Conference appeared first on Pharmaphorum.
from Pharmaphorum https://pharmaphorum.com/partner-content/speaker-interview-with-iveena-released-for-3rd-ophthalmic-drugs-conference/
0 notes
Text
New Horizon for Treatment of Inherited Retinal Dystrophy
Over the past twelve months there has been significant advancements in cell gene therapy for inherited retinal dystrophy, with an FDA approval of Spark Therapeutics’ Voretigene – the first gene therapy approved in ophthalmology. The company’s Clinical Ophthalmic Lead, Daniel Chung will be speaking at the 2nd annual Ophthalmic Drugs Conference in London on 26th November, where he will share his experiences on the development of Voretigene and its success. He will also discuss upcoming gene therapy trials and market access difficulties.
Daniel will be joined by a senior panel of big pharma and ophthalmic organisations to discuss the latest developments and innovations in ocular gene editing including:
Alan Stitt, Dean of Innovation and Impact, Queen’s University Belfast Mitchell de long, Vice President, Chemistry, Aerie Pharmaceuticals Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche Caroline Barelle, CEO, Elasmoge Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim Aniz Girach, Chief Medical Officer, Nightstar Therapeutics Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA David Silverman, Clinical Director, Ophthalmology, Roche
Programme highlights include recent advances in the treatment of glaucoma; recent applications of artificial intelligence in drug discovery and biomarkers and surrogate end-points from a regulatory perspective.
Website: www.ophthalmicdrugs.com/pr2
Sponsors: Aero Pump | Experimentica | Nemera
—end—
Contact Information:
For all media inquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email: [email protected]
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
The post New Horizon for Treatment of Inherited Retinal Dystrophy appeared first on Pharmaphorum.
from Pharmaphorum https://pharmaphorum.com/events/new-horizon-for-treatment-of-inherited-retinal-dystrophy/
0 notes
Text
Queen’s University Belfast and Santen to Present Opening Keynote this November
Hear from Queen’s University Belfast and Santen as they present the opening addresses this November.
Day 1 – Opening Keynote Address: New Strategies for Treating Retinal Vascular Diseases
Retinal vascular diseases are a leading cause of blindness in the Western world. Advancement in the clinical management of these diseases has been fast-paced, with new treatments becoming available as well as license extensions of existing treatments.*
Discover advancements in the treatment of ocular diseases as Professor Alan Stitt, Dean of Innovation and Impact, Queen’s University Belfast presents an overview of pathogenesis of ischaemic retinopathies, a disease that affects the immature retinal vascular system, as well as the cellular and molecular mechanisms of the disease. Check out the full presentation details online, as Professor Stitt looks ahead to new treatment pathways and improved use of preclinical evidence in the clinical setting to aid translation.
Day 2 – Opening Keynote Address: Glaucoma / retinoprotection treatments
Glaucoma is an optic neuropathy, specifically a neurodegenerative disease characterized by loss of retinal ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in glaucoma remains incompletely understood and a broad range of possible mechanisms have been implicated.*
Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen, USA will present the latest developments in the treatment of glaucoma, which will explore the novel and recently approved drugs in view, new devices to lower and control IOP and a case for pathways to retinoprotection.
Here’s a few of our last year’s attendees:
Aerie Pharmaceuticals | Alimera Sciences | Altacor, Ltd | Annexin Pharmaceuticals AB | APTAR PHARMA | Bayer (Schweiz) AG | Biozep AS | Boehringer Ingelheim Pharma GmbH & Co. KG | Elasmogen Ltd | Experimentica Ltd | Fresenius-Kabi | Leica Microsystems UK Ltd | MHRA | Midland Eye | Nanoptima Ltd | NEMERA | nicox | NightstarX | Novaliq GmbH | Optos | Ora Inc | Oxford BioMedica | Partner Grup Pazarlama Iletisimi ve Tur Tic Ltd Sti | Pharmaleads | PharmaMedic Consultancy Ltd | Roche | Roche Diagnostics Ltd | Roche Products Ltd | Santen Incorporated | Shire | Similasan + more!
Download the full 2017 attendee list in the download centre: www.ophthalmicdrugs.com/phpr
For those looking to attend, there is currently a £200 early-bird saving, ending September 28th.
SMi Presents the 2nd annual: Ophthalmic Drugs 2018 Date: 26th – 27th November 2018 Workshops: 28th November 2018 Location: Copthorne Tara Hotel, London UK Website: www.ophthalmicdrugs.com/phpr
Sponsors: Experimentica | Nemera
Sources: https://bit.ly/2BVa7lS | https://go.nature.com/2PEYouy
Follow ‘SMi Pharma‘ on LinkedIn for latest pharmaceutical industry updates.
—end—
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: [email protected]
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
The post Queen’s University Belfast and Santen to Present Opening Keynote this November appeared first on Pharmaphorum.
from Pharmaphorum https://pharmaphorum.com/partner-content/queens-university-belfast-and-santen-to-present-opening-keynote-this-november/
0 notes